- Home
- VRAX vs CNSP Comparison
VRAX vs CNSP Comparison
Compare VRAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- CNSP
- Stock Information
- Founded
- VRAX 2013
- CNSP 2017
- Country
- VRAX United Kingdom
- CNSP United States
- Employees
- VRAX N/A
- CNSP N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- CNSP Health Care
- Exchange
- VRAX Nasdaq
- CNSP Nasdaq
- Market Cap
- VRAX 7.3M
- CNSP 6.5M
- IPO Year
- VRAX 2022
- CNSP 2019
- Fundamental
- Price
- VRAX $1.90
- CNSP $0.14
- Analyst Decision
- VRAX
- CNSP Strong Buy
- Analyst Count
- VRAX 0
- CNSP 1
- Target Price
- VRAX N/A
- CNSP $0.50
- AVG Volume (30 Days)
- VRAX 282.7K
- CNSP 38.3M
- Earning Date
- VRAX 02-05-2025
- CNSP 03-31-2025
- Dividend Yield
- VRAX N/A
- CNSP N/A
- EPS Growth
- VRAX N/A
- CNSP N/A
- EPS
- VRAX N/A
- CNSP N/A
- Revenue
- VRAX $84,872.00
- CNSP N/A
- Revenue This Year
- VRAX $5,169.18
- CNSP N/A
- Revenue Next Year
- VRAX $66.97
- CNSP N/A
- P/E Ratio
- VRAX N/A
- CNSP N/A
- Revenue Growth
- VRAX 7.03
- CNSP N/A
- 52 Week Low
- VRAX $0.60
- CNSP $0.08
- 52 Week High
- VRAX $9.00
- CNSP $23.90
- Technical
- Relative Strength Index (RSI)
- VRAX 49.13
- CNSP 70.62
- Support Level
- VRAX $1.58
- CNSP $0.09
- Resistance Level
- VRAX $2.10
- CNSP $0.12
- Average True Range (ATR)
- VRAX 0.25
- CNSP 0.02
- MACD
- VRAX 0.01
- CNSP 0.00
- Stochastic Oscillator
- VRAX 47.88
- CNSP 52.83
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.